A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma

Colleen H. Druzgal, Zhong Chen, Ning T. Yeh, Giovana Thomas, Frank G. Ondrey, Dianne C. Duffey, Ronald J. Vilela, Kevin Ende, Linda McCullagh, Susan F. Rudy, Christine Muir, Laurie L. Herscher, John C. Morris, Paul S. Albert, Carter Van Waes

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background. Head and neck squamous cell carcinomas (HNSCCs) were previously shown to express a repertoire of cytokines and angiogenesis factors that contribute to malignant pathogenesis and are detectable in serum. Pretreatment and posttreatment serum levels of cytokines and angiogenesis factors were evaluated as markers for outcome in patients with HNSCC. Methods. Baseline cytokine and factor levels of 29 patients with HNSCC were compared with those of 15 age-matched and sex-matched controls, and pretreatment and posttreatment levels of 22 of the patients eligible for treatment and followed for a median of 37 months were compared. Results. Mean serum concentrations of interleukin (IL)-6, IL-8, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and growth regulated oncogene 1 (GRO-1) were increased in patients with HNSCC, but elevation of these factors was not associated with clinical outcome. However, changes in first posttreatment serum cytokine levels were observed for many of the patients consistent with response, progression, and survival. Later increases in IL-6 or HGF were observed in patients who had a relapse and inflammatory or infectious complications. A relationship between the change in the pretreatment and first posttreatment cytokine measurement with survival was detected for HGF, IL-8, IL-6, and VEGF using a Cox-proportional hazards model (p = .004, p = .06, p = .10, and p = .11). The association between longitudinal decreases in IL-6, IL-8, VEGF, and HGF throughout the follow-up with survival was detected with a time-dependent Cox model (p = .01, .07, .08, and .05, respectively). Conclusions. Longitudinal changes in serum HGF, IL-6, IL-8, and VEGF were detected with treatment response, relapse, or complications in individual patients and were associated with survival, with HGF showing the strongest relationship with survival. HGF, IL-6, IL-8, and VEGF merit investigation as markers of response, survival, and recurrence in larger prospective studies.

Original languageEnglish
Pages (from-to)771-784
Number of pages14
JournalHead and Neck
Volume27
Issue number9
DOIs
StatePublished - Sep 1 2005
Externally publishedYes

Fingerprint

Hepatocyte Growth Factor
Angiogenesis Inducing Agents
Interleukin-6
Interleukin-8
Cytokines
Vascular Endothelial Growth Factor A
Survival
Serum
Proportional Hazards Models
Recurrence
Therapeutics
Carcinoma, squamous cell of head and neck
Oncogenes
Prospective Studies
Growth

Keywords

  • Cytokines
  • Growth regulated oncogene 1
  • Interleukin-6
  • Interleukin-8
  • Squamous cell carcinoma
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. / Druzgal, Colleen H.; Chen, Zhong; Yeh, Ning T.; Thomas, Giovana; Ondrey, Frank G.; Duffey, Dianne C.; Vilela, Ronald J.; Ende, Kevin; McCullagh, Linda; Rudy, Susan F.; Muir, Christine; Herscher, Laurie L.; Morris, John C.; Albert, Paul S.; Van Waes, Carter.

In: Head and Neck, Vol. 27, No. 9, 01.09.2005, p. 771-784.

Research output: Contribution to journalArticle

Druzgal, CH, Chen, Z, Yeh, NT, Thomas, G, Ondrey, FG, Duffey, DC, Vilela, RJ, Ende, K, McCullagh, L, Rudy, SF, Muir, C, Herscher, LL, Morris, JC, Albert, PS & Van Waes, C 2005, 'A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma', Head and Neck, vol. 27, no. 9, pp. 771-784. https://doi.org/10.1002/hed.20246
Druzgal, Colleen H. ; Chen, Zhong ; Yeh, Ning T. ; Thomas, Giovana ; Ondrey, Frank G. ; Duffey, Dianne C. ; Vilela, Ronald J. ; Ende, Kevin ; McCullagh, Linda ; Rudy, Susan F. ; Muir, Christine ; Herscher, Laurie L. ; Morris, John C. ; Albert, Paul S. ; Van Waes, Carter. / A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. In: Head and Neck. 2005 ; Vol. 27, No. 9. pp. 771-784.
@article{f3b9e06d87d24e049bc8616794d59f1b,
title = "A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma",
abstract = "Background. Head and neck squamous cell carcinomas (HNSCCs) were previously shown to express a repertoire of cytokines and angiogenesis factors that contribute to malignant pathogenesis and are detectable in serum. Pretreatment and posttreatment serum levels of cytokines and angiogenesis factors were evaluated as markers for outcome in patients with HNSCC. Methods. Baseline cytokine and factor levels of 29 patients with HNSCC were compared with those of 15 age-matched and sex-matched controls, and pretreatment and posttreatment levels of 22 of the patients eligible for treatment and followed for a median of 37 months were compared. Results. Mean serum concentrations of interleukin (IL)-6, IL-8, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and growth regulated oncogene 1 (GRO-1) were increased in patients with HNSCC, but elevation of these factors was not associated with clinical outcome. However, changes in first posttreatment serum cytokine levels were observed for many of the patients consistent with response, progression, and survival. Later increases in IL-6 or HGF were observed in patients who had a relapse and inflammatory or infectious complications. A relationship between the change in the pretreatment and first posttreatment cytokine measurement with survival was detected for HGF, IL-8, IL-6, and VEGF using a Cox-proportional hazards model (p = .004, p = .06, p = .10, and p = .11). The association between longitudinal decreases in IL-6, IL-8, VEGF, and HGF throughout the follow-up with survival was detected with a time-dependent Cox model (p = .01, .07, .08, and .05, respectively). Conclusions. Longitudinal changes in serum HGF, IL-6, IL-8, and VEGF were detected with treatment response, relapse, or complications in individual patients and were associated with survival, with HGF showing the strongest relationship with survival. HGF, IL-6, IL-8, and VEGF merit investigation as markers of response, survival, and recurrence in larger prospective studies.",
keywords = "Cytokines, Growth regulated oncogene 1, Interleukin-6, Interleukin-8, Squamous cell carcinoma, Vascular endothelial growth factor",
author = "Druzgal, {Colleen H.} and Zhong Chen and Yeh, {Ning T.} and Giovana Thomas and Ondrey, {Frank G.} and Duffey, {Dianne C.} and Vilela, {Ronald J.} and Kevin Ende and Linda McCullagh and Rudy, {Susan F.} and Christine Muir and Herscher, {Laurie L.} and Morris, {John C.} and Albert, {Paul S.} and {Van Waes}, Carter",
year = "2005",
month = "9",
day = "1",
doi = "10.1002/hed.20246",
language = "English",
volume = "27",
pages = "771--784",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma

AU - Druzgal, Colleen H.

AU - Chen, Zhong

AU - Yeh, Ning T.

AU - Thomas, Giovana

AU - Ondrey, Frank G.

AU - Duffey, Dianne C.

AU - Vilela, Ronald J.

AU - Ende, Kevin

AU - McCullagh, Linda

AU - Rudy, Susan F.

AU - Muir, Christine

AU - Herscher, Laurie L.

AU - Morris, John C.

AU - Albert, Paul S.

AU - Van Waes, Carter

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Background. Head and neck squamous cell carcinomas (HNSCCs) were previously shown to express a repertoire of cytokines and angiogenesis factors that contribute to malignant pathogenesis and are detectable in serum. Pretreatment and posttreatment serum levels of cytokines and angiogenesis factors were evaluated as markers for outcome in patients with HNSCC. Methods. Baseline cytokine and factor levels of 29 patients with HNSCC were compared with those of 15 age-matched and sex-matched controls, and pretreatment and posttreatment levels of 22 of the patients eligible for treatment and followed for a median of 37 months were compared. Results. Mean serum concentrations of interleukin (IL)-6, IL-8, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and growth regulated oncogene 1 (GRO-1) were increased in patients with HNSCC, but elevation of these factors was not associated with clinical outcome. However, changes in first posttreatment serum cytokine levels were observed for many of the patients consistent with response, progression, and survival. Later increases in IL-6 or HGF were observed in patients who had a relapse and inflammatory or infectious complications. A relationship between the change in the pretreatment and first posttreatment cytokine measurement with survival was detected for HGF, IL-8, IL-6, and VEGF using a Cox-proportional hazards model (p = .004, p = .06, p = .10, and p = .11). The association between longitudinal decreases in IL-6, IL-8, VEGF, and HGF throughout the follow-up with survival was detected with a time-dependent Cox model (p = .01, .07, .08, and .05, respectively). Conclusions. Longitudinal changes in serum HGF, IL-6, IL-8, and VEGF were detected with treatment response, relapse, or complications in individual patients and were associated with survival, with HGF showing the strongest relationship with survival. HGF, IL-6, IL-8, and VEGF merit investigation as markers of response, survival, and recurrence in larger prospective studies.

AB - Background. Head and neck squamous cell carcinomas (HNSCCs) were previously shown to express a repertoire of cytokines and angiogenesis factors that contribute to malignant pathogenesis and are detectable in serum. Pretreatment and posttreatment serum levels of cytokines and angiogenesis factors were evaluated as markers for outcome in patients with HNSCC. Methods. Baseline cytokine and factor levels of 29 patients with HNSCC were compared with those of 15 age-matched and sex-matched controls, and pretreatment and posttreatment levels of 22 of the patients eligible for treatment and followed for a median of 37 months were compared. Results. Mean serum concentrations of interleukin (IL)-6, IL-8, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and growth regulated oncogene 1 (GRO-1) were increased in patients with HNSCC, but elevation of these factors was not associated with clinical outcome. However, changes in first posttreatment serum cytokine levels were observed for many of the patients consistent with response, progression, and survival. Later increases in IL-6 or HGF were observed in patients who had a relapse and inflammatory or infectious complications. A relationship between the change in the pretreatment and first posttreatment cytokine measurement with survival was detected for HGF, IL-8, IL-6, and VEGF using a Cox-proportional hazards model (p = .004, p = .06, p = .10, and p = .11). The association between longitudinal decreases in IL-6, IL-8, VEGF, and HGF throughout the follow-up with survival was detected with a time-dependent Cox model (p = .01, .07, .08, and .05, respectively). Conclusions. Longitudinal changes in serum HGF, IL-6, IL-8, and VEGF were detected with treatment response, relapse, or complications in individual patients and were associated with survival, with HGF showing the strongest relationship with survival. HGF, IL-6, IL-8, and VEGF merit investigation as markers of response, survival, and recurrence in larger prospective studies.

KW - Cytokines

KW - Growth regulated oncogene 1

KW - Interleukin-6

KW - Interleukin-8

KW - Squamous cell carcinoma

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=24644442153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644442153&partnerID=8YFLogxK

U2 - 10.1002/hed.20246

DO - 10.1002/hed.20246

M3 - Article

C2 - 15920746

AN - SCOPUS:24644442153

VL - 27

SP - 771

EP - 784

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 9

ER -